Concepedia

John F. Kurland

JF

Statistics

Publications

38

Citations

6.2K

H-Index

24

Active since

1980

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

The University of Texas MD Anderson Cancer Center

Bristol-Myers Squibb (United States)

Sidney Kimmel Comprehensive Cancer Center

AstraZeneca (United States)

John F. Kurland is an author at Memorial Sloan Kettering Cancer Center specializing in oncology, medicine, and cancer immunotherapy.

ORCID

Publications per year

1980–2025

38

Publications

38

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, George Lau, Masatoshi Kudo et al. · NEJM Evidence · 2022 · 1.4K citations · Full text

, , +16

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer

Do‐Youn Oh, Aiwu Ruth He, Shukui Qin et al. · NEJM Evidence · 2022 · 1.1K citations

, , +14

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

Christophe Massard, Michael S. Gordon, Sunil Sharma et al. · Journal of Clinical Oncology · 2016 · 845 citations · Full text

, , +17

Histone Deacetylase Inhibitors Radiosensitize Human Melanoma Cells by Suppressing DNA Repair Activity

Anupama Munshi, John F. Kurland, Takashi Nishikawa et al. · Clinical Cancer Research · 2005 · 347 citations · Full text

, , +13

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro, Stephen L. Chan, Robin Kate Kelley et al. · Annals of Oncology · 2024 · 312 citations · Full text

, , +16

1–5 of 38